XOMA Corp (XOMA) Q1 Earnings: The Breakdown
XOMA Corp missed Q1 2026 estimates as the market focuses on the pending $39.00 per share acquisition by Ligand Pharmaceuticals.
The numbers
XOMA reported financial results for the first quarter of 2026 that fell short of consensus estimates across both top and bottom lines. The company continues to operate as a royalty aggregator while awaiting the completion of its merger agreement.
Investors are currently evaluating the delta between the reported figures and the market's previous expectations.
- Revenue: $12.3 million vs. $13.9 million consensus estimate.
- EPS: $0.18 vs. $0.19 consensus estimate.
- Operating expenses: $12.8 million, driven by G&A costs and intangible asset amortization.
- Chart reference: estimate-vs-actual.
What drove the quarter
The revenue shortfall was primarily attributed to a year-over-year decline in income from contracts with customers. This contraction in core royalty-related revenue streams weighed on the quarterly performance.
Higher income from purchased receivables under the effective interest rate method provided a partial offset to the revenue decline. However, rising operating expenses exerted additional pressure on the bottom line.
- Revenue decline linked to reduced contract-based inflows compared to the prior year period.
- Operating expenses rose to $12.8 million due to higher administrative costs.
- Amortization of intangible assets contributed to the increased expense profile.
Forward guidance
Management has opted not to provide specific forward-looking financial guidance for the remainder of the fiscal year. The focus remains entirely on the pending acquisition by Ligand Pharmaceuticals.
Analysts have adjusted their outlooks to reflect the acquisition terms rather than standalone operational performance.
- H.C. Wainwright analyst Joseph Pantginis downgraded XOMA from Buy to Neutral.
- H.C. Wainwright set a price target of $39.00, aligning with the acquisition offer.
- Primary risk factors include regulatory approval, integration challenges, and legal risks related to the merger.
Fintwit's AI verdict
The Fintwit AI engine has analyzed the current positioning of XOMA Corp within the biotechnology royalty sector. The model evaluates the company's asset portfolio and the strategic implications of the Ligand Pharmaceuticals merger agreement.
Market participants are weighing the potential for the Contingent Value Right (CVR) against the risks inherent in the acquisition process. The following data provides a proprietary outlook on the stock's trajectory.